An experimental compound called BPC-157, marketed online for pain relief, injury healing, and enhancing athletic performance, is being used by many people for a range of medical conditions, even though there is little solid scientific evidence proving its safety or effectiveness. A recent analysis highlights that the peptide has not been approved for use in the United States but has gained a large following in a gray market, fueled by social media claims about muscle growth and recovery from injuries. It is often combined with another peptide, TB-500, in a popular combination known as the "Wolverine stack." In July, an advisory panel for the U.S. Food and Drug Administration (FDA) voted to allow pharmacy compounding of BPC-157, a move supported by U.S. Health Secretary Robert F. Kennedy Jr. However, the FDA has not yet made a final decision on whether compounding will be permitted. Previously, the agency had restricted the compounding of BPC-157 due to safety concerns and a lack of human trial data. Market analysts estimate that BPC-157 and similar peptides could grow into a $2 billion to $3 billion industry if they gain regulatory approval. Tracking the actual use of BPC-157 is difficult since it lacks a National Drug Code. To better understand its use, a data analytics firm called nference examined over 15 million medical records and found 1,039 patients whose doctors had manually noted the use of the peptide in clinical notes. Venky Soundararajan, who led the study, said this only gives a partial picture, as most doctors likely do not ask patients if they are taking BPC-157. The number of confirmed new users increased 33-fold between 2020 and 2026, with documented reasons for use including chronic pain, sports injuries, and gastrointestinal issues. Most users started taking BPC-157 for gastrointestinal problems or pain, often obtaining it from gray-market suppliers or compounding pharmacies. The user demographic has changed over time, with the proportion of male users increasing from 57% in 2020 to 70% in 2026, and the average age decreasing from 55 to 49. Among 972 users with recorded race data, 96% were white. Treatment outcomes were only recorded for a third of the participants. While some medical records noted symptom improvements, the limited data highlighted uncertainty about the peptide’s overall effectiveness, safety, and performance. When users stopped taking BPC-157, it was usually at the recommendation of their doctor, or due to reported side effects such as gastrointestinal, skin, and mental health issues. The FDA’s Adverse Event Monitoring System has recorded 10 serious adverse events involving BPC-157 since 2021, with eight of those reported in 2026. However, the FDA notes that these reports do not confirm that BPC-157 caused the adverse events, as they are submitted by patients, doctors, or businesses and are not independently verified. Dr. Flynn McGuire of the University of Utah, who is familiar with BPC-157 but not involved in the study, pointed out that many patients using the peptide were also taking other medications or undergoing other treatments. He said the lack of a control group, standardized treatment, or outcome measures made it impossible to determine how much of any reported recovery was due to BPC-157 versus natural healing, other treatments, or placebo effects.